Jensen Investment Management Inc. Buys 6,900 Shares of Hologic, Inc. $HOLX

Jensen Investment Management Inc. lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,230 shares of the medical equipment provider’s stock after purchasing an additional 6,900 shares during the quarter. Jensen Investment Management Inc.’s holdings in Hologic were worth $3,794,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Chung Wu Investment Group LLC acquired a new position in shares of Hologic during the second quarter worth $26,000. Caitong International Asset Management Co. Ltd raised its holdings in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in Hologic during the 1st quarter worth approximately $34,000. Cromwell Holdings LLC increased its position in Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 436 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Hologic during the first quarter valued at $42,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Finally, Morgan Stanley increased their price target on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $79.77.

Hologic Trading Down 0.1%

HOLX opened at $74.15 on Friday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $80.31. The firm has a market capitalization of $16.49 billion, a PE ratio of 30.77, a P/E/G ratio of 2.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company’s 50-day moving average is $69.76 and its 200 day moving average is $65.73.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the company posted $1.01 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.